<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054470</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270686</org_study_id>
    <secondary_id>U01CA069853</secondary_id>
    <secondary_id>P30CA054174</secondary_id>
    <secondary_id>SACI-IDD-01-44</secondary_id>
    <secondary_id>NCI-5330</secondary_id>
    <secondary_id>UTHSC-IDD-01-44</secondary_id>
    <nct_id>NCT00054470</nct_id>
  </id_info>
  <brief_title>Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for tumor cell growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and&#xD;
      either kill them or deliver tumor-killing substances to them without harming normal cells.&#xD;
      Combining tipifarnib with trastuzumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining tipifarnib with trastuzumab&#xD;
      in treating patients who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of tipifarnib and trastuzumab (Herceptin) in patients&#xD;
           with metastatic breast cancer.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral tipifarnib twice daily on days 1-21 and trastuzumab (Herceptin) IV over&#xD;
      30-90 minutes on day 1. Courses repeat every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-40 patients will be accrued for this study within 9-20&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the breast&#xD;
&#xD;
               -  HER2/neu 3+ by immunohistochemical staining&#xD;
&#xD;
                    -  2+ eligible provided HER2/neu positive by fluorescent in-situ hybridization&#xD;
                       (FISH)&#xD;
&#xD;
                    -  HER2/neu positive by FISH alone allowed&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  Must have received prior trastuzumab (Herceptin)&#xD;
&#xD;
          -  Patients with known brain metastases meeting any of the following criteria are not&#xD;
             eligible:&#xD;
&#xD;
               -  Require high-dose steroid therapy or enzyme-inducing anticonvulsant drugs&#xD;
&#xD;
               -  No prior cranial radiotherapy&#xD;
&#xD;
               -  Have progressive neurologic dysfunction that would preclude study evaluation&#xD;
&#xD;
               -  Have evidence of progressive CNS disease by CT scan or MRI&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Ejection fraction greater than 50% by MUGA or echocardiogram&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to tolerate oral&#xD;
             medication&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No significant traumatic injury within the past 21 days&#xD;
&#xD;
          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to tipifarnib (e.g., quinolones) or trastuzumab&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent medical illness that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bone marrow transplantation with high-dose chemotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
               -  Prior combination chemotherapy allowed&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy for cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior wide-field radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior modified radical mastectomy or lumpectomy with axillary node dissection allowed&#xD;
&#xD;
          -  Prior resection of metastatic lesions allowed&#xD;
&#xD;
          -  More than 21 days since prior major surgery&#xD;
&#xD;
          -  No prior surgery affecting absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior tipifarnib&#xD;
&#xD;
          -  More than 6 weeks since initiation of bisphosphonate therapy (if bone lesions are the&#xD;
             only site of measurable disease)&#xD;
&#xD;
          -  Bisphosphonate therapy may not be initiated during study&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent antacids within 2 hours of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garry Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

